Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant987 active trials8 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,216 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06167421 | Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy | not yet recruiting | N/A | 240 | Fudan UniversityOTHER | 0 | Dec 12, 2023 | clinicaltrials |
| NCT06160596 | Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis(ROSALIND) | recruiting | — | 1,020 | Cure 51OTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT06156267 | Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino | not yet recruiting | Early Phase 1 | 30 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06017284 | Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer(PTCA199-5) | recruiting | Phase 3 | 100 | Fudan UniversityOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05810792 | Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer(PANCEP-1) | not yet recruiting | Phase 2 | 50 | Sahlgrenska University HospitalOTHER | 0 | Nov 22, 2023 | clinicaltrials |
| NCT06126406 | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT04575363 | RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer(PaCaBioMarkeR) | recruiting | N/A | 90 | CHU de ReimsOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06010862 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | recruiting | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05988372 | Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) | not yet recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT05752812 | The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic Cancer | recruiting | — | 1,500 | Medical University of ViennaOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT05916261 | Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer | recruiting | Early Phase 1 | 54 | Ruijin HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06076252 | Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma | enrolling by invitation | N/A | 150 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06065891 | Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer(PALN) | recruiting | N/A | 300 | Jon UnossonOTHER | 2 | Oct 4, 2023 | clinicaltrials |
| NCT06055010 | Improving Pancreatic Cancer Care by the Use of Computational Science and Technology(IMPACT) | recruiting | — | 5,000 | UMC UtrechtOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06043466 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06043921 | Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel(ARTEMIS-PC) | recruiting | — | 150 | Invitae CorporationINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06028724 | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)(POPCORN) | recruiting | — | 782 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT04743479 | Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)(ESPRIT-AI) | recruiting | — | 5,000 | Changhai HospitalOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT03637569 | The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer | recruiting | — | 1,000 | Samsung Medical CenterOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT06009029 | SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study) | not yet recruiting | Phase 2 | 96 | Peking University Third HospitalOTHER | 0 | Aug 24, 2023 | clinicaltrials |
| NCT04592393 | Pancreas Cancer Surveillance Using an Abbreviated MRI | active not recruiting | N/A | 200 | Seoul National University HospitalOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05869474 | Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma | recruiting | N/A | 206 | Changhai HospitalOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03347162 | Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer | active not recruiting | — | 1,000 | Rigshospitalet, DenmarkOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05903703 | Canagliflozin With Gemcitabine in Pancreatic Carcinoma | not yet recruiting | N/A | 20 | Zhang Xiaofeng,MDOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05895214 | Mesopancreas Study in Pancreatic Cancer(MESOPANC-01) | not yet recruiting | — | 500 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05083247 | Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma(STEREOPAC) | recruiting | Phase 2 | 256 | Erasme University HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05361954 | Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors | not yet recruiting | Phase 1 | 36 | Sorrento Therapeutics, Inc.INDUSTRY | 0 | Apr 12, 2023 | clinicaltrials |
| NCT05802394 | The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer(MAP-03) | recruiting | N/A | 100 | Peking Union Medical College HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05802407 | The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer(MAP-02) | recruiting | N/A | 100 | Peking Union Medical College HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05243082 | Endoscopic Ultrasound Guided Radio Frequency Ablation of Pancreatic Neuroendocrine Neoplasms(ERFA-PNET) | recruiting | N/A | 20 | Oslo University HospitalOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05755594 | A Prospective Study on the Safety and Efficacy of Robot-assisted Pancreaticoduodenectomy | not yet recruiting | N/A | 100 | The First Affiliated Hospital of University of South ChinaOTHER | 0 | Mar 6, 2023 | clinicaltrials |
| NCT05755607 | A Multicenter Prospective Randomized Controlled Study of RPD Versus LPD | not yet recruiting | N/A | 200 | The First Affiliated Hospital of University of South ChinaOTHER | 0 | Mar 6, 2023 | clinicaltrials |
| NCT03311776 | BIOmarkers in Patients With Pancreatic Cancer ("BIOPAC")(BIOPAC) | recruiting | — | 5,000 | Inna Chen, MDOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05740111 | The PREPAIRD Study: Personalized Surveillance for Early Detection of Pancreatic Cancer in High Risk Individuals(PREPAIRD) | enrolling by invitation | N/A | 200 | Oslo University HospitalOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05433935 | Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas | recruiting | — | 5,000 | Zhejiang UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05679583 | Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer | recruiting | Phase 2 | 25 | Yonsei UniversityOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT04949282 | Spanish Series of Patients Treated With the Radionuclide Lutetium177(SEPTRALU) | recruiting | — | 5,000 | Sociedad Española de Medicina Nuclear e Imagen MolecularOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05356039 | Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer(SQUARE) | recruiting | — | 300 | Umeå UniversityOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05620732 | Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T | recruiting | N/A | 20 | Shenzhen University General HospitalOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT05611359 | Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer(HOPE-1) | not yet recruiting | N/A | 60 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Nov 10, 2022 | clinicaltrials |
| NCT05585554 | Locally Advanced Pancreatic Cancer Treated With ABLAtivE Stereotactic MRI-guided Adaptive Radiation Therapy(LAP-ABLATE) | not yet recruiting | N/A | 267 | Viewray Inc.INDUSTRY | 0 | Oct 19, 2022 | clinicaltrials |
| NCT03621644 | Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer | active not recruiting | N/A | 133 | Viewray Inc.INDUSTRY | 2 | Oct 14, 2022 | clinicaltrials |
| NCT03747588 | The Comparision of Minimally-invasive and Open Pancreaticoduodenectomy for Pancreatic Cancer(MIOPP) | recruiting | N/A | 100 | Peking Union Medical College HospitalOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT04361162 | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | active not recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05524090 | PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer(PREOPANC-4) | recruiting | — | 223 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05316480 | Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms | not yet recruiting | Phase 2 | 42 | Fudan UniversityOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT05268692 | Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP | recruiting | Phase 2 / Phase 3 | 500 | Kochi UniversityOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT03785743 | Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma | recruiting | N/A | 200 | Tongji HospitalOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05155878 | Prognostic Factors in Periampullary Tumors and Cysts | recruiting | — | 500 | Umeå UniversityOTHER | 1 | Jan 5, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Dec 12, 2023source: clinicaltrials